Amorphous Vortioxetine Preparation via Spray Drying
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing vortioxetine, a drug for treating major depressive disorder and generalized anxiety disorder, often result in crystalline forms that require significant energy for dissolution, leading to lower bioavailability and stability issues, necessitating the development of an efficient, economical, and eco-friendly process for producing amorphous forms with high purity and stability.
Innovation Solution
A process involving the preparation of amorphous vortioxetine hydrobromide and free base through the removal of solvents from organic solutions, using techniques like spray drying and freeze drying, which results in a stable, free-flowing powder with high purity and minimal residual solvents, and the formation of solid dispersions with polymers to enhance bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Use of energy by moving object
If crystalline forms of vortioxetine are used, then the drug substance is stable and easy to handle, but significant energy is required for dissolution and bioavailability is reduced
Solution Approach 1:
The patent applies parameter changes by transforming the physical state of vortioxetine from crystalline to amorphous form. This fundamental change in molecular arrangement eliminates the need for energy-intensive dissolution while enhancing bioavailability, as the amorphous form dissolves more readily in biological fluids without requiring additional energy input.
Solution Approach 2:
The invention utilizes phase transitions by converting vortioxetine from its stable crystalline phase to an amorphous phase through specific processing techniques. This phase transition results in a form that requires minimal energy for dissolution and exhibits superior bioavailability, directly resolving the contradiction between energy requirement and bioavailability.
2Reliability
If amorphous forms of drugs are prepared, then dissolution characteristics and bioavailability are improved, but stability and purity control become more challenging
Solution Approach 1:
The patent employs intermediaries by incorporating stabilizing excipients and polymers in the formulation of amorphous vortioxetine. These intermediary substances interact with the amorphous drug molecules to prevent crystallization and maintain structural stability, thereby preserving the high bioavailability benefits while addressing stability concerns.
Solution Approach 2:
The invention creates composite materials by formulating amorphous vortioxetine with stabilizing agents, polymers, and excipients. This composite approach maintains the amorphous structure's superior dissolution characteristics while the incorporated materials provide structural support and stability, resolving the contradiction between bioavailability and stability.
3Ease of manufacture
If conventional preparation processes are used, then crystalline vortioxetine is produced, but the process is energy-intensive and less eco-friendly
Solution Approach 1:
The patent applies parameter changes by modifying the preparation process parameters to produce amorphous form directly, eliminating the need for energy-intensive crystallization steps. This results in a more efficient manufacturing process with reduced energy consumption and improved eco-friendliness while maintaining ease of manufacture.
Solution Approach 2:
The invention replaces mechanical crystallization processes with alternative methods such as spray drying, freeze drying, or solvent evaporation techniques that directly produce amorphous forms. This substitution eliminates energy-intensive mechanical operations while maintaining process efficiency and reducing overall energy consumption.
4Reliability
If high purity amorphous vortioxetine is achieved, then bioavailability is enhanced, but residual solvent control becomes more critical
Solution Approach 1:
The patent applies continuity of useful action by implementing continuous solvent removal processes during amorphous vortioxetine preparation. Techniques such as controlled evaporation, vacuum drying, or freeze drying are used continuously to eliminate residual solvents while maintaining the amorphous structure, thereby preserving high bioavailability without compromising safety.
Solution Approach 2:
The invention converts the potential harm of residual solvents into a benefit by using the solvent removal process itself to enhance the amorphous structure's stability. The controlled evaporation or drying process that removes harmful residual solvents also prevents crystallization, maintaining the high bioavailability amorphous form while eliminating the harmful factor.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process yields amorphous vortioxetine forms that are stable, highly pure, and exhibit improved bioavailability, meeting regulatory standards and ensuring consistent pharmaceutical performance.
Implementation Method 1
using techniques like spray drying and freeze drying
Implementation Method 2
obtaining the amorphous vortioxetine hydrobromide by the removal of the solvent
Implementation Method 3
using techniques like spray drying and freeze drying
Data Source
AI summary
The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a process for preparation of amorphous vortioxetine free base. The invention also relates to pharmaceutical compositions comprising an amorphous vortioxetine or hydrobromide salt thereof for oral administration for treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).